ACP-ML: A sequence-based method for anticancer peptide prediction.

Cancer is a serious malignant tumor and is difficult to cure. Chemotherapy, as a primary treatment for cancer, causes significant harm to normal cells in the body and is often accompanied by serious side effects. Recently, anti-cancer peptides (ACPs) as a type of protein for treating cancers dominated research into the development of new anti-tumor drugs because of their ability to specifically target and destroy cancer cells. The screening of proteins with cancer-inhibiting properties from a large pool of proteins is key to the development of anti-tumor drugs. However, it is expensive and inefficient to accurately identify protein functions only through biological experiments due to their complex structure. Therefore, we propose a new prediction model ACP-ML to effectively predict ACPs. In terms of feature extraction, DPC, PseAAC, CTDC, CTDT and CS-Pse-PSSM features were used and the most optimal feature set was selected by comparing combinations of these features. Then, a two-step feature selection process using MRMD and RFE algorithms was performed to determine the most crucial features from the most optimal feature set for identifying ACPs. Furthermore, we assessed the classification accuracy of single learning models and different strategies-based ensemble models through ten-fold cross-validation. Ultimately, a voting-based ensemble learning method is developed to predict ACPs. To validate its effectiveness, two independent test sets were used to perform tests, achieving accuracy of 90.891 % and 92.578 % respectively. Compared with existing anticancer peptide prediction algorithms, the proposed feature processing method is more effective, and the proposed ensemble model ACP-ML exhibits stronger generalization capability and higher accuracy.

Unsupervised construction of gene regulatory network based on single-cell multi-omics data of colorectal cancer.

Identifying gene regulatory networks (GRNs) at the resolution of single cells has long been a great challenge, and the advent of single-cell multi-omics data provides unprecedented opportunities to construct GRNs. Here, we propose a novel strategy to integrate omics datasets of single-cell ribonucleic acid sequencing and single-cell Assay for Transposase-Accessible Chromatin using sequencing, and using an unsupervised learning neural network to divide the samples with high copy number variation scores, which are used to infer the GRN in each gene block. Accuracy validation of proposed strategy shows that approximately 80% of transcription factors are directly associated with cancer, colorectal cancer, malignancy and disease by TRRUST; and most transcription factors are prone to produce multiple transcript variants and lead to tumorigenesis by RegNetwork database, respectively. The source code access are available at: https://github.com/Cuily-v/Colorectal_cancer.

Feature selection combined with top-down and bottom-up strategies for survival analysis: A case of prognostic prediction in glioblastoma.

Over the last decades, molecular signatures have attracted extensive attention in cancer research. However, most of the reported biomarkers show a weak distinguishing ability in predicting the survival risks of patients. Actually, univariate analysis is generally considered in regression analysis, which makes the existing statistical methods ineffective. Furthermore, there is too much human involvement in the ways of classifying patients with high and low risk. Last but not least, the participation of therapy after conservative surgery also makes the survival analysis more complex. In order to solve these problems, we propose a solid method of feature selection which combines top-down and bottom-up strategies. The top-down strategy is to randomly extract some genes each time and select candidate genes through cumulative voting. The bottom-up strategy is to fully enumerate the selected genes and to use a clustering algorithm to classify samples. We analyzed glioblastoma data from the Cancer Genome Atlas (TCGA) and got candidate signatures. The results of simulation data, as well as an independent test set the Chinese Glioma Genome Atlas (CGGA), verified the reliability of the method and validity of the selected features.